Following prolonged treatment, CLL and DLBCL patients can acquire resistance to BTK inhibitors, ibrutinib or acalabrutinib, through mutations in BTK and its substrate phospholipase C gamma 2 (PLCG2), MYD88, and CARD11 [18, 20]. This evidence concerns the gene PLCG2 and diffuse large B-cell lymphoma.